Instead of approving the new Alzheimer’s drug donanemab this month, as was expected, the U.S. Food and Drug Administration (FDA) will now require the experimental medication be scrutinized more closely by an expert panel.
FDA Delays Decision on New Alzheimer’s Drug, Donanemab
March 8, 2024
Related News
Benefit Advisors & Employees - Want to know more?
Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com
Clients: Contact your Client Relations Manager
